EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately held Shanghai company developing bispecific and T-cell-engager antibodies for solid tumours. Its lead candidate EMB-01 has Phase 2 clearance in China, and it presented its ProTCE platform at AACR 2026.
| Headquarters | Shanghai, China |
|---|---|
| Listing | Private |
| Lead asset / stage | EMB-01 Phase 2 IND cleared — China |
| Latest event | EpimAb announced presentation of its ProTCE platform at AACR 2026. |